A new treatment arm of the I-SPY2 TRIAL will include patritumab, an investigational anti-HER3 monoclonal antibody

Two articles published today in the July 7, 2016 issue of the New England Journal of Medicine highlight the innovative nature and utility of I-SPY2

Pre-surgery Combination Therapy Lessens Short and Long-term Toxicity and Could Mean Development of Fewer Recurrent Metastatic Breast Cancers

QuantumLeap Healthcare Collaborative Announces Inclusion of MERCK’s KEYTRUDA (pembrolizumab) and MEDIVATION’s Talazoparib PARP-Inhibitor for I-SPY 2 TRIAL in Breast Cancer

MK-2206 plus standard neoadjuvant therapy beneficial in all hormone receptor (HR)-negative, all HER2-positive, and HR-negative/HER2-positive tumors

Plexxikon’s drug candidate, PLX3397, has been selected for study in the I-SPY 2 TRIAL

The investigational drug neratinib and standard chemotherapy was beneficial for hormone receptor (HR)-negative, HER2-positive primary breast cancer in the I-SPY 2 trial

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta’s lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL

Summary

Highly Anticipated Multi-Agent Trial Opens at Major U.S. Medical Sites.